Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. PolyNovo Limited
  6. News
  7. Summary
    PNV   AU000000PNV0

POLYNOVO LIMITED

(PNV)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 12/03
1.405 AUD   +2.18%
11/08Australia shares close lower as healthcare, tech stocks drag
RE
11/05Polynovo Ropes in Former Director as Interim CEO
MT
11/04PolyNovo Limited Announces Executive Changes
CI
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

09/20/2021 | 11:54pm EST

PolyNovo announced that the first patient has been enrolled in the pivotal arm of the BARDA funded burn study. The trial is being conducted in 20 US and 5 Canadian burn centres comprising up to 150 full thickness burn patients in a comparative study against the existing standard of care. It is estimated to take 3 years, recruitment rate dependant. The study has BARDA funding support of $15 million USD.


ę S&P Capital IQ 2021
All news about POLYNOVO LIMITED
11/08Australia shares close lower as healthcare, tech stocks drag
RE
11/05Polynovo Ropes in Former Director as Interim CEO
MT
11/04PolyNovo Limited Announces Executive Changes
CI
10/17Miners, energy stocks help Australian shares inch higher
RE
09/20PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded ..
CI
09/09POLYNOVO : COO Resigns
MT
09/09PolyNovo Limited Announces Anthony Kaye Resignation as Chief Operating Officer
CI
08/26POLYNOVO : Widens Net Loss Despite Revenue Rise in FY21 on Higher Employee, Overhead Expen..
MT
08/25Polynovo Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/22PolyNovo Limited Provides an Update on its Hernia Device
CI
More news
Financials
Sales 2022 47,2 M 33,0 M 33,0 M
Net income 2022 -0,74 M -0,52 M -0,52 M
Net cash 2022 4,40 M 3,08 M 3,08 M
P/E ratio 2022 -2 927x
Yield 2022 -
Capitalization 929 M 652 M 651 M
EV / Sales 2022 19,6x
EV / Sales 2023 12,5x
Nbr of Employees -
Free-Float 89,6%
Chart POLYNOVO LIMITED
Duration : Period :
PolyNovo Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POLYNOVO LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 1,41 AUD
Average target price 2,12 AUD
Spread / Average Target 50,7%
EPS Revisions
Managers and Directors
Robert Maxwell Johnston Chief Executive Officer
Jan-Marcel Gielen Chief Financial Officer & Secretary
David John Williams Non-Executive Chairman
Tim Moore Principal Scientist
Joshua Cheetham Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
POLYNOVO LIMITED-63.79%646
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726